JP2019501865A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501865A5
JP2019501865A5 JP2018517576A JP2018517576A JP2019501865A5 JP 2019501865 A5 JP2019501865 A5 JP 2019501865A5 JP 2018517576 A JP2018517576 A JP 2018517576A JP 2018517576 A JP2018517576 A JP 2018517576A JP 2019501865 A5 JP2019501865 A5 JP 2019501865A5
Authority
JP
Japan
Prior art keywords
crystalline hemihydrate
crystalline
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517576A
Other languages
English (en)
Japanese (ja)
Other versions
JP6770775B2 (ja
JP2019501865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/057372 external-priority patent/WO2017066775A1/en
Publication of JP2019501865A publication Critical patent/JP2019501865A/ja
Publication of JP2019501865A5 publication Critical patent/JP2019501865A5/ja
Priority to JP2020159855A priority Critical patent/JP7358317B2/ja
Application granted granted Critical
Publication of JP6770775B2 publication Critical patent/JP6770775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2018517576A 2015-10-16 2016-10-17 （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法 Active JP6770775B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020159855A JP7358317B2 (ja) 2015-10-16 2020-09-24 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562242797P 2015-10-16 2015-10-16
US62/242,797 2015-10-16
US201562267672P 2015-12-15 2015-12-15
US62/267,672 2015-12-15
US201662301537P 2016-02-29 2016-02-29
US62/301,537 2016-02-29
US201662352380P 2016-06-20 2016-06-20
US62/352,380 2016-06-20
PCT/US2016/057372 WO2017066775A1 (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020159855A Division JP7358317B2 (ja) 2015-10-16 2020-09-24 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法

Publications (3)

Publication Number Publication Date
JP2019501865A JP2019501865A (ja) 2019-01-24
JP2019501865A5 true JP2019501865A5 (enExample) 2019-12-05
JP6770775B2 JP6770775B2 (ja) 2020-10-21

Family

ID=57209916

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2018517576A Active JP6770775B2 (ja) 2015-10-16 2016-10-17 （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法
JP2020159855A Active JP7358317B2 (ja) 2015-10-16 2020-09-24 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2022079226A Pending JP2022107001A (ja) 2015-10-16 2022-05-13 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2023096042A Pending JP2023113917A (ja) 2015-10-16 2023-06-12 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2024041977A Pending JP2024073591A (ja) 2015-10-16 2024-03-18 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2025133177A Pending JP2025166113A (ja) 2015-10-16 2025-08-08 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2025133176A Pending JP2025166112A (ja) 2015-10-16 2025-08-08 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2020159855A Active JP7358317B2 (ja) 2015-10-16 2020-09-24 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2022079226A Pending JP2022107001A (ja) 2015-10-16 2022-05-13 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2023096042A Pending JP2023113917A (ja) 2015-10-16 2023-06-12 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2024041977A Pending JP2024073591A (ja) 2015-10-16 2024-03-18 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2025133177A Pending JP2025166113A (ja) 2015-10-16 2025-08-08 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
JP2025133176A Pending JP2025166112A (ja) 2015-10-16 2025-08-08 （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法

Country Status (13)

Country Link
US (39) US20170129902A1 (enExample)
EP (3) EP4647129A2 (enExample)
JP (7) JP6770775B2 (enExample)
KR (2) KR20250010141A (enExample)
CN (7) CN120289468A (enExample)
AU (5) AU2016340167B2 (enExample)
BR (1) BR122022024925B1 (enExample)
CA (8) CA3002220C (enExample)
IL (3) IL314468A (enExample)
MX (2) MX387822B (enExample)
RU (1) RU2018117889A (enExample)
SG (8) SG10201913987UA (enExample)
WO (1) WO2017066775A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2836833A1 (de) 1978-08-23 1980-04-10 Volkswagenwerk Ag Brennkraftmaschine mit in zwei reihen angeordneten zylindern
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
CN120289468A (zh) 2015-10-16 2025-07-11 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MX2019010733A (es) 2017-03-09 2019-11-01 Abbvie Inc Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US20210163409A1 (en) * 2017-07-19 2021-06-03 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of pyrrolidine derivatives
CA3095487A1 (en) * 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
EP3845521B1 (en) * 2018-08-31 2024-11-06 Suzhou Pengxu Pharmatech Co., Ltd. Synthesis methods for upadacitinib and intermediate thereof
CN110872250B (zh) * 2018-08-31 2023-01-10 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成乌西替尼中的用途
WO2020063939A1 (zh) * 2018-09-29 2020-04-02 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
CN111217819B (zh) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 乌帕替尼的合成方法
EP3891151A1 (en) 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN109369659B (zh) * 2018-12-06 2020-10-27 浙江师范大学 一种jak抑制剂的合成方法
WO2020115213A1 (en) 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate of a selective jak1 inhibitor
CN109705011B (zh) * 2019-01-18 2021-02-19 浙江师范大学 一种乌帕替尼中间体的合成方法及中间体
WO2020177645A1 (zh) * 2019-03-01 2020-09-10 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
WO2020202183A1 (en) 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110229160A (zh) * 2019-06-11 2019-09-13 南京新酶合医药科技有限公司 (5-甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪-2-基)氨基甲酸乙酯的制备方法
CN110117245B (zh) * 2019-06-21 2021-03-02 浙江师范大学 一种jak抑制剂中间体的合成方法
WO2021005484A1 (en) * 2019-07-11 2021-01-14 Mankind Pharma Ltd. Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
BR112022005765A2 (pt) * 2019-09-30 2022-06-21 Abbvie Inc Tratamento contra afecções espondiloartríticas e psoriáticas com upadacitinib
CN111072543B (zh) * 2019-11-13 2021-06-04 北京海美桐医药科技有限公司 一种(3r,4s)-4-乙基吡咯烷-3-羧酸类化合物的制备方法及其应用
KR20220118522A (ko) * 2019-12-19 2022-08-25 쿠리아 스페인, 에스.에이.유. 우파다시티닙의 제조를 위한 방법 및 중간체
WO2021176473A1 (en) * 2020-03-05 2021-09-10 Mylan Laboratories Limited A process for the preparation of upadacitinib and its intermediates
WO2021244323A1 (zh) * 2020-06-05 2021-12-09 苏州科睿思制药有限公司 一种乌帕替尼的晶型及其制备方法和用途
WO2022007629A1 (zh) 2020-07-08 2022-01-13 苏州科睿思制药有限公司 乌帕替尼的晶型及其制备方法和用途
WO2022044037A1 (en) 2020-08-24 2022-03-03 Mylan Laboratories Limited An improved process for the preparation of upadacitinib intermediate
CN114621127A (zh) * 2020-12-08 2022-06-14 苏州鹏旭医药科技有限公司 一种取代二氢吡咯的合成方法
KR20230167057A (ko) * 2021-04-07 2023-12-07 애브비 인코포레이티드 유파다시티닙의 공결정
CN115724781A (zh) * 2021-08-30 2023-03-03 凯特立斯（深圳）科技有限公司 一种合成乌帕替尼关键手性中间体的方法
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
EP4460503A4 (en) * 2022-01-06 2025-12-03 Msn Laboratories Private Ltd R&D Center IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB
AU2022435654A1 (en) 2022-01-20 2024-08-01 Renata Pharmaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
CN114315679B (zh) * 2022-01-21 2024-08-30 杭州新博思生物医药有限公司 一种乌帕替尼手性中间体的制备方法
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2024075131A1 (en) * 2022-10-03 2024-04-11 Natco Pharma Limited Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof
AU2024240383A1 (en) 2023-03-22 2025-10-09 Abbvie Inc. Methods of treating pediatric patients with upadacitinib
CN121127242A (zh) 2023-05-23 2025-12-12 艾伯维公司 用乌帕替尼治疗白癜风的方法
US20250049789A1 (en) 2023-08-08 2025-02-13 Abbvie Inc. Methods of treating alopecia araeta
CN117534678A (zh) * 2023-11-08 2024-02-09 浙江宏元药业股份有限公司 一种乌帕替尼的新结晶形式及其制备方法
CN117285535B (zh) * 2023-11-27 2024-02-02 中节能万润股份有限公司 一种乌帕替尼中间体及成盐中间体的制备方法
CN117285537B (zh) * 2023-11-27 2024-02-06 中节能万润股份有限公司 一种乌帕替尼的制备方法
CN117285536B (zh) * 2023-11-27 2024-02-20 中节能万润股份有限公司 一种乌帕替尼中间体的制备方法
CN117447481A (zh) * 2023-12-23 2024-01-26 潍坊医学院 一种乌帕替尼-焦谷氨酸盐的无定形物及其制备方法与应用
WO2025149011A1 (zh) * 2024-01-11 2025-07-17 浙江华海药业股份有限公司 一种乌帕替尼或其水合物的合成工艺
CN118047785A (zh) * 2024-03-07 2024-05-17 和鼎（南京）医药技术有限公司 制备乌帕替尼及其中间体的方法
KR20250146517A (ko) 2024-04-01 2025-10-13 주식회사 파마코스텍 유파다시티닙(upadacitinib)의 알킬 포함 술폰산염 화합물, 및 이의 제조방법
WO2025221754A1 (en) 2024-04-17 2025-10-23 Abbvie Inc. Upadacitinib for use in the treatment of giant cell arteritis
CN118370734B (zh) * 2024-06-26 2024-10-01 山东则正医药技术有限公司 一种乌帕替尼缓释片及其制备方法

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3663559A (en) 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4053474A (en) 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
CA2028235C (en) 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
CA2073500C (en) 1990-01-11 2008-03-25 Phillip Dan Cook Compositions and methods for detecting and modulating rna activity and gene expression
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
DE69233701T2 (de) 1991-03-18 2008-04-10 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
WO1992022552A1 (en) 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
CA2156918A1 (en) 1993-02-26 1994-09-01 Deen Tulshian 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5736540A (en) 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5763137A (en) 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
US5703244A (en) 1996-11-21 1997-12-30 Abbott Laboratories Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds
AU738545C (en) 1997-02-05 2004-06-17 Merck Sharp & Dohme Corp. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
CA2322311C (en) 1998-03-04 2009-10-13 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US6245801B1 (en) 1998-09-14 2001-06-12 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
DE19853665B4 (de) 1998-11-20 2005-06-30 Siemens Ag Fahrzeugkommunikationssystem und Verfahren zum Austausch von Daten in einem Kraftfahrzeug
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
EP1325006A2 (en) 2000-08-07 2003-07-09 Neurogen Corporation Heterocyclic compounds as ligands of the gaba a? receptor
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
JP2005529850A (ja) 2002-02-19 2005-10-06 ファルマシア・イタリア・エス・ピー・エー 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
CA2501947A1 (en) 2002-10-09 2004-04-22 Scios Inc. Azaindole derivatives as inhibitors of p38 kinase
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602004018811D1 (de) 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
EA011446B1 (ru) 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
EP1773840B1 (de) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
CN101098872B (zh) 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
JP5270167B2 (ja) 2004-12-21 2013-08-21 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形
ES2411975T3 (es) 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
JP5190270B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 細胞周期キナーゼ阻害剤としてのピラゾロピリミジン
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
WO2006107771A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
KR20080035698A (ko) 2005-08-16 2008-04-23 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
AU2006295397A1 (en) * 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
JP4551962B2 (ja) 2005-09-23 2010-09-29 コーリー ファーマシューティカル グループ，インコーポレイテッド １Ｈ−イミダゾ［４，５−ｃ］ピリジンおよびその類似体のための方法
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
CA2635231C (en) 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
EP2029541B1 (en) 2006-04-03 2009-12-30 F. Hoffmann-Roche AG Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
MX2009001551A (es) 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
EP2068869A4 (en) 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
JP5287253B2 (ja) 2007-01-12 2013-09-11 アステラス製薬株式会社 縮合ピリジン化合物
CN101230059B (zh) * 2007-01-23 2011-08-17 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
JP2010532312A (ja) 2007-01-30 2010-10-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
PE20090996A1 (es) 2007-04-02 2009-07-15 Palau Pharma Sa Derivados de pirrolopirimidina como inhibidores de cinasa jak3
HUE046488T2 (hu) 2007-05-07 2020-03-30 Evonik Operations Gmbh Gyorsított drogfelszabadulást biztosító, bélben oldódó bevonatot tartalmazó szilárd adagolási forma
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2009085310A1 (en) 2007-12-26 2009-07-09 Teva Pharmaceutical Industries Ltd. Extended-release pharmaceutical compositions containing zolpidem
ATE517107T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitoren
MX2010008198A (es) 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
PL2250172T3 (pl) 2008-02-25 2012-01-31 Hoffmann La Roche Pirolopirazynowe inhibitory kinazy
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
US20120276206A1 (en) 2008-03-28 2012-11-01 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
CN101638423B (zh) * 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 根皮苷衍生物及其制备方法和用途
KR101275980B1 (ko) 2009-02-24 2013-06-17 머크 캐나다 인크. Ｃｒｔｈ２ 수용체 길항제로서의 인돌 유도체
WO2010117796A2 (en) 2009-03-30 2010-10-14 Codexis, Inc. Processes for the preparation of alpha-chloroketones from carboxylic acids
CN102395589A (zh) 2009-04-14 2012-03-28 安斯泰来制药株式会社 稠合吡咯并吡啶衍生物
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
FR2947276B1 (fr) 2009-06-24 2012-10-26 Seppic Sa Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides
US8361962B2 (en) 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
WO2011013082A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
CN102711476B (zh) * 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
CN102711470A (zh) 2009-12-01 2012-10-03 雅培制药有限公司 新的三环化合物
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
CA2788526A1 (en) 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
US20130310427A1 (en) 2010-06-09 2013-11-21 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2012149280A2 (en) 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
US20130072470A1 (en) * 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
PT2874630T (pt) 2012-07-20 2019-01-31 Zoetis Services Llc Regime de dosagem para inibidores de janus quinase (jak)
EP3431475B1 (en) 2013-02-21 2021-04-07 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
MA38347A1 (fr) 2013-02-22 2017-10-31 Pfizer Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
BR112015021980A2 (pt) 2013-03-15 2017-07-18 Global Blood Therapeutics Inc compostos e seus usos para a modulação de hemoglobina
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
WO2015061665A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
CN106794126A (zh) 2014-08-27 2017-05-31 艾伯维公司 局部配制品
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
AU2016305590A1 (en) 2015-08-13 2018-02-15 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
KR102029124B1 (ko) 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
CN120289468A (zh) 2015-10-16 2025-07-11 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
PT3383363T (pt) 2015-11-30 2021-03-03 Anacor Pharmaceuticals Inc Formulações farmacêuticas tópicas para o tratamento de afeções relacionadas com inflamações
WO2017126488A1 (ja) 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
WO2017143014A1 (en) 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
KR102413459B1 (ko) 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
MX2019010733A (es) 2017-03-09 2019-11-01 Abbvie Inc Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
KR20240148324A (ko) 2022-01-13 2024-10-11 애브비 인코포레이티드 유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법

Similar Documents

Publication Publication Date Title
JP2019501865A5 (enExample)
JP7346353B2 (ja) リファキシミン
ES2881395T3 (es) Composiciones y métodos para inhibir la actividad de la arginasa
JP2022095640A (ja) ナトリウム（２ｒ，５ｓ，１３ａｒ）－７，９－ジオキソ－１０－（（２，４，６－トリフルオロベンジル）カルバモイル）－２，３，４，５，７，９，１３，１３ａ－オクタヒドロ－２，５－メタノピリド［１’，２’：４，５］ピラジノ［２，１－ｂ］［１，３］オキサゼピン－８－オレート
ES2606752T3 (es) Método para la preparación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2- carboxamida
JP2011168587A5 (enExample)
CA2980888C (en) Crystal of 3,5-disubstituted benzene alkynyl compound
WO2015130966A1 (en) Antiviral agents
CA2950309A1 (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP2013543867A5 (enExample)
RS65987B1 (sr) Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
JP2011132229A5 (enExample)
US20100105724A1 (en) Crystalline and amorphous forms of palonosetron hydrochloride
FI3694863T3 (fi) Lorlatinibin vapaan emäksen hydraatin kidemuoto
CA2729769C (en) Salts of hiv inhibitor compounds
JP2020536893A5 (enExample)
JP2016528242A5 (enExample)
JP2008535848A5 (enExample)
JP2020502224A5 (enExample)
CA2603654A1 (en) Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof
JP2022160667A (ja) アクリジニウム臭化物の製造方法
JP2013520488A5 (enExample)
JPS62228016A (ja) 非−白金抗癌薬によりひき起こされる嘔吐の軽減用治療剤
WO2011104637A2 (en) Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
ES2924432T3 (es) Polimorfos cristalinos de un agonista del receptor de la acetilcolina muscarínica